Matching articles for "Clostridiodes difficile"
Issue 1745 · January 5, 2026
Gepotidacin (Blujepa) — A New Antibiotic for Uncomplicated UTI

The FDA has approved gepotidacin ( Blujepa – GSK), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, for oral treatment of uncomplicated urinary tract infections (uUTI) in female patients…

Med Lett Drugs Ther. 2026 Jan 5; 68(1745):1-3 doi:10.58347/tml.2026.1745a
The FDA has approved gepotidacin ( Blujepa – GSK), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, for oral treatment of uncomplicated urinary tract infections (uUTI) in female patients ≥12 years old who weigh ≥40 kg. Gepotidacin is the first triazaacenaphthylene antibiotic to be approved in the US.
Issue 1632 · September 6, 2021
Treatment of Clostridioides difficile Infection

Clostridioides (formerly Clostridium ) difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. Guidelines on management of CDI have recently been updated.

Med Lett Drugs Ther. 2021 Sep 6; 63(1632):137-41
Clostridioides (formerly Clostridium ) difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. Guidelines on management of CDI have recently been updated.
Issue 1616 · January 25, 2021 Free
Antibacterial Drugs for Community-Acquired Pneumonia

Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in…

Med Lett Drugs Ther. 2021 Jan 25; 63(1616):10-5
Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) were updated in 2019.
Issue 1567 · March 11, 2019
Rifamycin (Aemcolo) for Treatment of Travelers' Diarrhea

The FDA has approved rifamycin ( Aemcolo – Cosmo/ Aries), a minimally absorbed oral antibiotic, for treatment of adults with travelers' diarrhea (TD) caused by noninvasive strains of Escherichia coli . It is…

Med Lett Drugs Ther. 2019 Mar 11; 61(1567):39-40
The FDA has approved rifamycin ( Aemcolo – Cosmo/ Aries), a minimally absorbed oral antibiotic, for treatment of adults with travelers' diarrhea (TD) caused by noninvasive strains of Escherichia coli . It is not recommended for treatment of diarrhea that is complicated by fever and/or bloody stools. Topical and injectable formulations of rifamycin have been used in Europe for other indications for many years.